Document Detail


Economic assessment of thrombocytopenia: CATCH Registry.
MedLine Citation:
PMID:  20503623     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Thrombocytopenia is associated with increased patient risk. However, the costs of this complication are not well defined. This study assessed the impact of thrombocytopenia on in-hospital costs using results from CATCH, an observational study that examined 1988 consecutive patients receiving prolonged heparin therapy (> or =96 h). Thrombocytopenia was defined as: (group 1) an absolute reduction in platelet count to <150 x 10(9)/L; (group 2) a relative reduction in platelet count of >50% from admission levels; or (group 3) both criteria. We found that the development of thrombocytopenia was associated with significantly higher total in-hospital costs for all groups: (group 1) (difference, $8,222; 95% CI, $5,020-$11,425; P<.001); (group 2) (difference, $15,429; 95% CI, $7,472-$23,385; P<.001); and (group 3) (difference, $27,077; 95% CI, $22,901-$31,252; P<.001). However, in our adjusted model, longer lengths-of-stay and greater use of blood transfusions accounted for most incremental in-hospital cost differences.
Authors:
Eric L Eisenstein; Emily F Honeycutt; Kevin J Anstrom; Richard C Becker; Christopher B Granger; Sunil V Rao; Marc E Jolicoeur; E Magnus Ohman;
Related Documents :
16340473 - Reasons for modification of generic highly active antiretroviral therapeutic regimens a...
21807563 - Oxygen therapy for cerebral malaria.
14516033 - Arthroscopic treatment of osteochondral lesions of the talus.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of medical systems     Volume:  34     ISSN:  0148-5598     ISO Abbreviation:  J Med Syst     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-27     Completed Date:  2010-06-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806056     Medline TA:  J Med Syst     Country:  United States    
Other Details:
Languages:  eng     Pagination:  379-86     Citation Subset:  IM    
Affiliation:
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA. eric.eisenstein@duke.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Blood Transfusion / economics,  statistics & numerical data
Costs and Cost Analysis
Female
Fibrinolytic Agents / adverse effects
Heparin / adverse effects
Hospital Costs / statistics & numerical data*
Humans
Length of Stay / economics,  statistics & numerical data
Male
Middle Aged
Registries*
Thrombocytopenia / chemically induced,  economics*,  therapy
United States
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Collaborative simulation of soft-tissue deformation for virtual surgery applications.
Next Document:  Predictors of informal health payments: the example from Turkey.